Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaAlexandre V. Hirayama, Cameron J. Turtle, Mazyar Shadman et al.|Blood|2022Cited by 6
CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II StudyNicolas Gazeau, Jordan Gauthier, Salvatore Fiorenza et al.|Blood|2022Cited by 2
Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II StudyNicolas Gazeau, Jordan Gauthier, Salvatore Fiorenza et al.|Transplantation and Cellular Therapy|2023Cited by 1
Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALLJordan Gauthier, Cameron J. Turtle, Nicolas Gazeau et al.|Transplantation and Cellular Therapy|2023Cited by 1
CAR T-Cell Therapy for Acute Myeloid Leukemia: Critical Role for TNFα Signaling to Overcome Target Antigen HeterogeneityErik L. Kimble, Cameron J. Turtle, Salvatore Fiorenza et al.|Transplantation and Cellular Therapy|2025Cited by 0